# US 2019/0167724 A1 · Neuroprotective composition, preparation process thereof and medical uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0167724 A1
- Document ID: US20190167724A1
- Status: Published application
- Kind: A1
- Application number: 15/830,200
- Filed: 2017-12-04
- Published: 2019-06-06
- Earliest claimed: 2017-12-04
- Assignees: Caire Medical-Biotechnology International Co.
- Applicants: Caire Medical-Biotechnology International Co.
- Inventors: Te-Fu CHEN; Kuo-Chuan Wang
- Web page: https://patentgrep.com/patent/US20190167724A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/26: Psychostimulants, e.g. nicotine, cocaine
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C12N 5/0664: {Dental pulp stem cells, Dental follicle stem cells}
- C12N 2502/1364: Dental pulp stem cells, dental follicle stem cells
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention relates to a neuroprotective composition derived from mesenchymal stem cells, especially a neuroprotective composition derived from the primary culture of dental pulp mesenchymal stem cells. The invention also relates to a process for preparing the neuroprotective composition, as well as the medical uses of the neuroprotective composition in the treatment of neurological diseases associated with neuronal damage, including subarachnoid hemorrhage and Parkinson's disease.

## Claims

### Claim 1

A method for treating a neurological disorder associated with neuronal damage in a subject, comprising administering to said subject an effective amount of a neuroprotective composition to suppress neuronal damage; wherein the neuroprotective composition is obtainable by a process comprising the steps of:
(i) culturing mesenchymal stem cells in a serum-free basal culture medium for at least 3 hours to obtain a cell culture; and
(ii) processing the cell culture obtained in step (i) to obtain an aqueous fraction with a molecular weight of no more than about 5 kDa as the neuroprotective composition.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the mesenchymal stem cells are dental pulp mesenchymal stem cells.

### Claim 3 (depends on 2)

The method according to claim 2, wherein the processing step (ii) comprises ultrafiltrating the cell culture obtained in step (i) through a membrane having a molecular weight cut-off of 5 kDa, thereby collecting a filtrate passing through the membrane.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the neurological disorders associated with neuronal damage is selected from the group consisting of amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, Huntington's disease, muscular dystrophy, multiple sclerosis, ischemic stroke, hemorrhagic stroke, transient ischemic attack (TIA), and traumatic brain injury (TBI).

### Claim 5 (depends on 4)

The method according to claim 4, wherein the neurological disorder associated with neuronal damage is selected from the group consisting of Alzheimer's disease, Parkinson's disease, Huntington's disease, ischemic stroke, primary SAH, secondary SAH, traumatic SAH and intracerebral hemorrhage (ICH), transient ischemic attack (TIA), and traumatic brain injury (TBI).

### Claim 6 (depends on 5)

The method according to claim 5, wherein the neurological disorder associated with neuronal damage is selected from the group consisting of Parkinson's disease, primary SAH and secondary SAH.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the subject is selected from the group consisting of human and non-human vertebrates.

### Claim 8

A method of inhibiting cerebral neuroinflammation in a subject in need thereof, comprising administering an effective amount of a neuroprotective composition, thereby inhibiting cerebral neuroinflammation in the subject; wherein the neuroprotective composition is obtainable by a process comprising the steps of:
(i) culturing mesenchymal stem cells in a serum-free basal culture medium for at least 3 hours to obtain a cell culture; and
(ii) processing the cell culture obtained in step (i) to obtain an aqueous fraction with a molecular weight of no more than about 5 kDa as the neuroprotective composition.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the subject is selected from the group consisting of human and non-human vertebrates.
